Tag: Brexpiprazole

Approved by the FDA in 2015, Rexulti (brexpiprazole) is an atypical antipsychotic that acts as a serotonin-dopamine activity modulator (SDAM). Its specific binding profile sets it apart, but **how is Rexulti different from other antipsychotics** and what does that mean for treatment?

Rexulti (brexpiprazole) is a prescription atypical antipsychotic approved by the FDA for multiple uses in mental health treatment. For those considering this medication, knowing exactly **what does Rexulti do for you** is a critical first step to discussing it with a healthcare provider.

Approved by the FDA in 2015, Rexulti, with the generic name brexpiprazole, is an atypical antipsychotic medication used to treat several mental health conditions. It belongs to a newer class of antipsychotic drugs and works by adjusting the levels of key neurotransmitters in the brain to help improve mood, behavior, and thinking.

The term "Rex medicine" does not refer to a single, specific pharmaceutical product, but rather is a naming convention found in various medications with distinct active ingredients and therapeutic purposes. Understanding the specific drug is critical to know what purpose is Rex medicine used for, as applications range from mental health to treating infections or relieving allergies.

According to the National Alliance on Mental Illness (NAMI), about 1% of US adults live with schizophrenia, a condition often managed with antipsychotic medications like Rexulti. Understanding **what is the pharmacology of Rexulti** reveals how its unique mechanism of action addresses the neurotransmitter imbalances associated with conditions such as schizophrenia, major depressive disorder, and Alzheimer's-related agitation.

For over two decades, the U.S. Food and Drug Administration (FDA) has not approved a new drug specifically for post-traumatic stress disorder (PTSD), highlighting a significant unmet need for more effective treatments. A promising combination drug therapy was recently considered, but ultimately denied, leading to intense focus on other investigational options, including psychedelic-assisted therapies, in the search for what is the new drug for PTSD.